ERYTHROMYCIN ESTOLATE for Carcinoid syndrome: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where ERYTHROMYCIN ESTOLATE was used for Carcinoid syndrome.
Most Reported Side Effects for ERYTHROMYCIN ESTOLATE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug hypersensitivity | 76 | 77.6% | 0 | 33 |
| Infection | 69 | 70.4% | 0 | 33 |
| Drug intolerance | 68 | 69.4% | 0 | 33 |
| International normalised ratio fluctuation | 68 | 69.4% | 0 | 33 |
| Nausea | 61 | 62.2% | 0 | 33 |
| Vomiting | 61 | 62.2% | 0 | 33 |
| Bloody discharge | 60 | 61.2% | 0 | 32 |
| Lyme disease | 58 | 59.2% | 0 | 33 |
| Therapeutic product effect incomplete | 58 | 59.2% | 0 | 32 |
| Fatigue | 56 | 57.1% | 0 | 33 |
| Dizziness | 36 | 36.7% | 0 | 32 |
| Hypoaesthesia | 35 | 35.7% | 0 | 32 |
| Iron deficiency | 35 | 35.7% | 0 | 32 |
| Malaise | 35 | 35.7% | 0 | 32 |
| Pain in extremity | 35 | 35.7% | 0 | 31 |
Other Indications for ERYTHROMYCIN ESTOLATE
Other Drugs Used for Carcinoid syndrome
TELOTRISTAT ETHYL (2,954)
OCTREOTIDE (1,367)
LANREOTIDE (581)
EVEROLIMUS (128)
SANDOSTATIN LAR (31)
SUNITINIB MALATE (15)
CAPECITABINE (13)
TEMOZOLOMIDE (11)
SANDOSTATIN LAR DEPOT (9)
BEVACIZUMAB (8)